Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.42 (-4.05% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 36 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While LXRX currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.87) and Max Pain ($1.49) forces dealer call-delta covering toward $2.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Lexicon Pharmaceuticals Inc. (LXRX) dropped -4.05% to $1.42, trading at 20% of its 52-week range ($1.1 – $2.68). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
scanx.trade report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of sotagliflozin on platelet
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #922 by composite RQD confidence (27/100, grade E) and #408 by equity capitalization ($658.5M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with LXRX at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LXRX
ACTIVE
Lexicon Pharmaceuticals Inc. | E | 27/100 | — | 96.0% | -31.5% | -4.05% | $658.5M | Benchmark Subject |
| ABUS Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -1.64% | $656.0M | /abus-vs-lxrx → |
| IMMX Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -3.76% | $661.6M | /immx-vs-lxrx → |
| ANL Adlai Nortye Group Ltd. | D | 47/100 | — | — | — | -7.10% | $662.0M | /anl-vs-lxrx → |
| BCAX Bicara Therapeutics Inc. | E | 30/100 | — | — | -35.0% | -6.17% | $643.9M | /bcax-vs-lxrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $49.8M | -$50.3M | -$67.9M | -$67.9M | $185.0M | $49.4M |
| FY2024 (FY) | 2024-12-31 | $6.0M | -$200.4M | -$178.8M | -$179.8M | $298.4M | $100.3M |
| FY2023 (FY) | 2023-12-31 | $1.1M | -$177.1M | -$161.9M | -$161.9M | — | — |
As of 2026-11-02, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.42 (-4.05% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LXRX last traded at $1.42 (-4.05% on volume of 2,444,226 shares), positioning the stock -24.06% below its 50-day simple moving average ($1.87) and -24.87% below its 200-day simple moving average ($1.89). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 20.3% percentile with a 14-day RSI of 36.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.26 to $1.58).
Why LXRX Stock dropped -4.05% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, LXRX scores 27 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the rating points to a company with negative operating economics and cash burn, where the balance sheet is the main mitigating factor. The implication for a prospective investor is that valuation cannot be anchored to current earnings or cash flow, since neither is positive in the source data, and the risk of further capital needs is a central consideration.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $49.8M | $-48.9M | $-50.3M | N/A | $-67.9M | $34.3M | $49.4M |
| FY 2024 | $6.0M | $-197.1M | $-200.4M | N/A | $-179.8M | $66.7M | $100.3M |
| FY 2023 | $1.1M | $-171.8M | $-177.1M | N/A | $-161.9M | N/A | N/A |
Per the SEC financials, every reported period shows an operating loss and net loss, with FCF negative in each year. Revenue rose from $1.1M in FY 2023 to $49.8M in FY 2025, while net income moved from $-177.1M to $-50.3M, indicating narrowing losses in absolute terms. Per the market data, gross margin is 96%, but operating margin and net margin are both -60%, and ROIC is -31.5%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5 out of 9. Cash fell from $66.7M to $34.3M while debt declined from $100.3M to $49.4M across FY 2024 to FY 2025, and the Debt/Equity ratio is 0.46.
Per the recent news feed, LXRX appears across several market-wire items:
Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND signal is bullish with a severity score of 91 and a Macro Tailwind Score of 92/100. The signal states a 2.97x True Net Liquidity beta with an r of -0.19 and attributes the tailwind to the current Fed/TGA/RRP liquidity print of $5,746B. The signal is macro-driven and does not reflect company-specific fundamentals. Note the tension: the macro signal is bullish while the RQD rating and RED-flagged risk item are bearish on fundamentals.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE and no butterfly links are provided, so no upstream or downstream dependencies can be mapped from the source data. Sector correlations beyond the stated Health Care / Biotechnology classification are not available in source data. The main 2nd-order channel visible in the data is liquidity sensitivity: the macro signal implies that LXRX's price responds to shifts in net liquidity, so a tightening of liquidity conditions, as reflected in the Fed, TGA, and RRP components, would be a ripple risk. Investors should also watch the high-yield spread, which the signal cites at +2 bps, as an indicator of financing conditions for cash-consuming issuers.
Real-time company headlines, analyst actions, and sector developments for Lexicon Pharmaceuticals Inc. (LXRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
scanx.trade report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o
Welcome to the LXRX (Lexicon Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on LXRX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Lexicon Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on LXRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.48 (52-wk range $1.10 - $2.68), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).